Stock listing

Frankfurt:09R Skye Bioscience, Inc. Aktie

German listing (Frankfurt) of Skye Bioscience, Inc. · home listing NASDAQ:SKYE

Follow Skye Bioscience, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:SKYE

$1.53 USD -0.02 (-1.3%)

Close on Oct 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:SKYE

Since Jul 6, 2026 +1,641% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
$1.50 – $1.60 USDOct 19, 2026
Volume
22,552 sharesOct 19, 2026
Market value
$6.77M USDAt the close on Oct 19, 2026 · price × 4.43M shares outstanding
Skye Bioscience, Inc. logo
Ticker
Frankfurt:09R
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Replays

  • Skye Bioscience (NASDAQ:SKYE) Q4 2025 Earnings Call

    Tue, Mar 10, 2026 · 4:30 PM ET

    Watch Transcript

  • Skye Bioscience (NASDAQ:SKYE) Q3 2025 Earnings Call

    Mon, Nov 10, 2025 · 4:30 PM ET

    Watch Transcript

  • Skye Bioscience (NASDAQ:SKYE) Q2 2025 Earnings Call

    Thu, Aug 07, 2025 · 4:30 PM ET

    Watch Transcript

Latest news

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Aug 14, 2026

SkyVolt Energy Signs LOI with Modular Data Center Company Nodiac.ai, Unlocking Potential Additional Revenue from strategic Existing and Future Energy Development Assets

Jun 18, 2026

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

May 20, 2026

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 12, 2026

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 11, 2026

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Apr 7, 2026

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Apr 2, 2026

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 10, 2026

Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026

Mar 5, 2026

Halozyme reports full year 2025 record revenue of $1.4 billion and reiterates strong 2026 Financial Guidance

Feb 17, 2026

Issued by another party

All Skye Bioscience, Inc. news

Decks

Skye Bioscience, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
19 in the last 12 months · 130 in all · newest Aug 14, 2026 · oldest 2021
Calls
6 calls with a replay · 6 with a transcript · latest Mar 10, 2026
Decks
9 decks · latest Aug 14, 2026

Where Skye Bioscience, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:SKYE · Home listingNASDAQUnited StatesUSD
LS Exchange:A3ES4XLS ExchangeGermanyEUR
Lang & Schwarz:A3ES4XLang & SchwarzGermanyEUR
BOATS:SKYEBOATSUnited StatesUSD
Frankfurt:09R · This pageFrankfurtGermanyEUR
Dusseldorf:09RDusseldorfGermanyEUR

Log in to ask 6ix AI your own questions about Skye Bioscience, Inc.